权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Northern Alliance Advanced Therapies Treatment Centre

北方联盟先进疗法治疗中心

基本信息

批准号：
104233
负责人：
金额：
$ 961.3万
依托单位：
THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST
依托单位国家：
英国
项目类别：
Collaborative R&D
财政年份：
2018
资助国家：
英国
起止时间：
2018 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=104233
关键词：
Northern Alliance Advanced Therapies Treatment

项目摘要

"The Northern Alliance Advanced Therapies Treatment Centre (NAATTC) is a group of NHS hospitals and services. NAATTC has a wide geographical reach across Scotland and the North of England and is responsible for the health care of 15 million NHS patients.Advanced therapies are becoming increasingly available with a growing number of companies developing them both in the UK and worldwide. They are based on the administration of gene- and cell-based products in specialities such as haematology, autoimmunity, hepatology, cardiology and ophthalmology. They are thought to be more effective than existing treatments and provide treatments for diseases where currently no effective therapy exists. However most are still in clinical trials.Advanced therapies present significant challenges to healthcare providers compared with existing treatments. Addressing these challenges in the NHS will require development and dissemination of new skills for nurses, doctors, hospital pharmacists, NHS managers, and commissioners such as NHS England and the clinical commissioning groups (CCGs). It will also require changes in the way treatment is delivered.The changes required in the NHS can only be properly implemented through partnership with the companies that are developing and providing advanced therapies to the NHS. Manufacturers will need assistance with clinical trials to ensure optimal trial design, effective recruitment into clinical trials, and long term follow up of outcomes. The manufacturing and distributing processes are complex and it is critical that these systems are integrated effectively with those within the NHS.The NAATTC already has considerable experience of delivering advanced therapies and clinical trials and will use this experience to work with manufacturers (and their supply chains) to significantly increase their capacity to deliver advanced therapies effectively, safely, and seamlessly to patients within the NHS. It will identify gaps in our existing provision and develop solutions to narrow and eliminate the gaps. It will share the best practice that it develops to other ATTCs and to other NHS organisations.The outcomes will be to deliver these promising therapies to NHS patients and to make the NHS a global leader in their delivery, creating health and wealth for the UK."

“北方联盟高级疗法治疗中心（NAATTC）是一组NHS医院和服务。NAATTC在苏格兰和英格兰北部拥有广泛的地理覆盖范围，负责1500万NHS患者的医疗保健。随着越来越多的公司在英国和世界各地开发先进的治疗方法，先进的治疗方法越来越多。它们基于血液学、自身免疫学、肝脏病学、心脏病学和眼科学等专业中基于基因和细胞的产品的管理。它们被认为比现有的治疗方法更有效，并为目前没有有效治疗方法的疾病提供治疗。然而，大多数仍处于临床试验阶段。与现有的治疗方法相比，先进的治疗方法对医疗保健提供者提出了重大挑战。在NHS解决这些挑战将需要开发和传播新的技能，护士，医生，医院药剂师，NHS管理人员和专员，如NHS英格兰和临床调试组（CCG）。这也将需要改变治疗的方式，只有通过与开发和提供先进疗法的公司合作，才能适当地实施NHS所需的改变。制造商将需要临床试验方面的协助，以确保最佳的试验设计、有效的临床试验招募和长期的结果随访。制造和分销过程是复杂的，这是至关重要的，这些系统是有效地集成与那些在NHS. NAATTC已经有相当丰富的经验，提供先进的治疗和临床试验，并将利用这方面的经验，与制造商（及其供应链），以显着提高他们的能力，提供先进的治疗有效，安全，和无缝的病人在NHS.它将确定我们现有供应中的差距，并制定缩小和消除差距的解决方案。它将与其他ATTC和其他NHS组织分享其开发的最佳实践。其结果将是为NHS患者提供这些有前途的疗法，并使NHS成为全球领先的治疗提供者，为英国创造健康和财富。"